BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Enormous Credit And All that You Really want To Be aware - 2Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- 3'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
- 4Flourishing in a Remote Workplace: Individual Techniques
- 5Man triggers smoke bomb during failed crypto robbery
- 2025 Yachting Editors' Choice Awards: Yachts
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- The Response Uncovered: Disentangling the Secrets of the Universe
- A Couple of Modest Guitars for 2024
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- Step by step instructions to Guarantee the Strength and Life span of Your Pre-assembled Home
- The most effective method to Explore Moral Situations in Brain research with Your Certification
